Results 71 to 80 of about 14,723 (146)

L-asparaginase induces IP3R-mediated ER Ca2+ release by targeting µ-OR1 and PAR2 and kills acute lymphoblastic leukemia cells

Cell Death Discovery
L-asparaginase is a standard therapeutic option for acute lymphoblastic leukemia (aLL), a hematologic cancer that claims the most lives of pediatric cancer patients.
Jung Kwon Lee, Hamza Kamran, Ki-Young Lee   +2 more
doaj   +1 more source

PKA inhibition kills l-asparaginase-resistant leukemic cells from relapsed acute lymphoblastic leukemia patients

Cell Death Discovery
Despite the success in treating newly diagnosed pediatric acute lymphoblastic leukemia (aLL), the long-term cure rate for the 20% of children who relapse is poor, making relapsed aLL the primary cause of cancer death in children.
Jung Kwon Lee, Xidi Wang, Jinghua Wang, Jesusa L. Rosales, Ki-Young Lee   +4 more
doaj   +1 more source

Molecular phylogenetic characterization of L-asparaginase-producing endophytic fungi inhabiting Prunus africana and Periploca linearifolia: Effect of incubation time and pH on enzyme production

Scientific African
The therapeutic use of L-asparaginase derived from bacterial sources has been constrained by various challenges, including toxicity and repression. This has prompted the exploration of alternative sources, particularly eukaryotic microorganisms like ...
Dennis Kipngenoh Cheruiyot, George Isanda Omwenga, Eliud Nyaga Mwaniki Njagi   +2 more
doaj   +1 more source

Gene sequencing, cloning, and expression of the recombinant L- Asparaginase of Pseudomonas aeruginosa SN4 strain in Escherichia coli

Biological Journal of Microorganism, 2016
Introduction: L- asparaginase is in an excessive demand in medical applications and in food treating industries, the request for this therapeutic enzyme is growing several folds every year.
Arastoo Badoei-dalfard, Zahra Karami, Narjes Ramezani-pour   +2 more
doaj  

Enzyme therapy in a structural light. [PDF]

IUCrJ
Cooper J.
europepmc   +1 more source

Prevention of Subsequent L-Asparaginase Hypersensitivity in Children Through Premedication: A Single-Center Experience. [PDF]

J Pediatr Pharmacol Ther
Saligupta P, Choed-Amphai C, Sathitsamitphong L, Lao-Araya M.   +3 more
europepmc   +1 more source

Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity. [PDF]

Blood Adv
Lefeivre T, Grosu TI, Tudose C, Jones L, León TE, Wynne K, Oliviero G, Smith OP, Trinquand A, Mansour MR, Ryan CJ, Bond J.   +11 more
europepmc   +1 more source

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT. [PDF]

Curr Oncol
Eng DZS, Khadadah F, Perusini MA, Al-Shaibani E, Atenafu EG, Bankar A, Davidson M, Richard-Carpentier G, Maze D, Yee K, Schimmer A, Gupta V, Chan S, Kim DDH, Schuh A, Minden M, Sibai H.   +16 more
europepmc   +1 more source

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL. [PDF]

Blood Adv
Anderson DR, Gangaraju R, Sedhom WG, Hamulyák EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A.   +34 more
europepmc   +1 more source

Impact of treatment-induced thrombosis on the prognosis of acute lymphoblastic leukaemia: a protocol for a systematic review and meta-analysis. [PDF]

BMJ Open
Mkhwanazi ZA, Fabunmi OA, Nkambule BB.
europepmc   +1 more source